Oncotype DX (ODX), a 21-gene assay, predicts the recurrence risk in early breast cancer; however, it has high costs and long testing times. We aimed to identify clinicopathological factors that can predict the ODX risk group and serve as alternatives to the ODX test. This retrospective study included 547 estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and lymph node-negative breast cancer patients who underwent ODX testing. Based on the recurrence scores, three ODX risk categories (low: 0–15, intermediate: 16–25, and high: 26–100) were established in patients aged ≤50 years (n= 379), whereas two ODX risk categories (low: 0–25 and high: 26–100) were established in patients aged >50 years (n= 168). Factors selected for analysis included body mass index, menopausal status, type of surgery, and pathological and immunohistochemical features. The ODX risk groups showed significant association with histologic grade (p= 0.0002), progesterone receptor expression (p< 0.0001), Ki-67 (p< 0.0001), and p53 expression (p= 0.023) in patients aged ≤50 years. In patients aged >50 years, tumor size (p= 0.022), Ki-67 (p= 0.001), and p53 expression (p= 0.001) were significantly associated with the risk group. Certain clinicopathological factors can predict the ODX risk group and enable decision-making on adjuvant chemotherapy; these factors differ according to age.
Oncotype DX（ODX）是一种21基因检测方法，用于预测早期乳腺癌的复发风险，但其检测成本较高且耗时较长。本研究旨在确定能够预测ODX风险分组的临床病理学因素，以作为ODX检测的替代方案。这项回顾性研究纳入了547例雌激素受体阳性、人表皮生长因子受体2阴性且淋巴结阴性的乳腺癌患者，这些患者均接受了ODX检测。根据复发评分，在年龄≤50岁的患者（n=379）中建立了三个ODX风险类别（低风险：0–15分，中风险：16–25分，高风险：26–100分），而在年龄>50岁的患者（n=168）中则建立了两个ODX风险类别（低风险：0–25分，高风险：26–100分）。分析选用的因素包括体重指数、绝经状态、手术类型以及病理学和免疫组化特征。在年龄≤50岁的患者中，ODX风险分组与组织学分级（p=0.0002）、孕激素受体表达（p<0.0001）、Ki-67（p<0.0001）和p53表达（p=0.023）显著相关。在年龄>50岁的患者中，肿瘤大小（p=0.022）、Ki-67（p=0.001）和p53表达（p=0.001）与风险分组显著相关。某些临床病理学因素能够预测ODX风险分组，并有助于辅助化疗的决策制定；这些因素因年龄而异。
肿瘤(癌症)患者之家